EP0906310A4 - BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES -g(b) 3? SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE - Google Patents
BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES -g(b) 3? SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITEInfo
- Publication number
- EP0906310A4 EP0906310A4 EP97929769A EP97929769A EP0906310A4 EP 0906310 A4 EP0906310 A4 EP 0906310A4 EP 97929769 A EP97929769 A EP 97929769A EP 97929769 A EP97929769 A EP 97929769A EP 0906310 A4 EP0906310 A4 EP 0906310A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- obesity
- agonists
- diabetes
- selective
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1929596P | 1996-06-07 | 1996-06-07 | |
| US19295P | 1996-06-07 | ||
| GBGB9614191.6A GB9614191D0 (en) | 1996-07-05 | 1996-07-05 | Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity |
| GB9614191 | 1996-07-05 | ||
| PCT/US1997/009536 WO1997046556A1 (fr) | 1996-06-07 | 1997-06-03 | BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES β3 SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0906310A1 EP0906310A1 (fr) | 1999-04-07 |
| EP0906310A4 true EP0906310A4 (fr) | 1999-09-01 |
Family
ID=26309646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97929769A Ceased EP0906310A4 (fr) | 1996-06-07 | 1997-06-03 | BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES -g(b) 3? SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0906310A4 (fr) |
| JP (1) | JP2000511903A (fr) |
| AU (1) | AU712057B2 (fr) |
| CA (1) | CA2257206A1 (fr) |
| WO (1) | WO1997046556A1 (fr) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673615C (fr) | 2000-01-21 | 2013-07-16 | Novartis Ag | Combinaisons comprenant des inhibiteurs de la dipeptidylpeptidase- iv et des agents antidiabetiques |
| WO2001054728A1 (fr) * | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3 |
| ATE267204T1 (de) * | 2000-03-31 | 2004-06-15 | Pfizer Prod Inc | Verfahren zur herstellung von substituierten pyridinen |
| BR0112409A (pt) * | 2000-07-13 | 2003-07-22 | Lilly Co Eli | Agonistas para beta3 adrenérgico |
| US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| IL154928A0 (en) | 2000-11-10 | 2003-10-31 | Lilly Co Eli | 3-substituted oxindole beta 3 agonists |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| DE60215028T2 (de) | 2001-08-14 | 2007-03-15 | Eli Lilly And Co., Indianapolis | Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes |
| EP1444224B1 (fr) | 2001-08-14 | 2006-05-03 | Eli Lilly And Company | Agonistes de beta-3 a base d'oxyndole 3-substitue |
| CA2459454A1 (fr) | 2001-09-14 | 2003-03-27 | Bayer Pharmaceuticals Corporation | Derives de benzofurane et de dihydrobenzofurane utiles comme agonistes du beta-3 adrenorecepteur |
| AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| ATE297925T1 (de) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
| AU2002357084A1 (en) | 2002-01-11 | 2003-07-30 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| ITMI20022389A1 (it) * | 2002-11-12 | 2004-05-13 | Nicox Sa | Farmaci per le disfunzioni sessuali. |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| PL3345895T3 (pl) | 2003-04-11 | 2020-05-18 | Ptc Therapeutics, Inc. | Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby |
| WO2005061489A1 (fr) * | 2003-12-24 | 2005-07-07 | Prosidion Limited | Derives heterocycliques utilises comme agonistes des recepteurs gpcr |
| WO2005097127A2 (fr) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques |
| EP1838706A1 (fr) | 2004-12-24 | 2007-10-03 | Prosidion Limited | Agonistes du récepteur couplé aux protéines g |
| WO2007003960A1 (fr) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes du gpcr |
| WO2007003961A2 (fr) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Agonistes de gpcr |
| BRPI0616077B8 (pt) | 2005-09-14 | 2021-05-25 | Takeda Pharmaceuticals Co | composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos |
| CA2624030A1 (fr) | 2005-09-29 | 2007-04-12 | Tianying Jian | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
| BRPI0710213A2 (pt) | 2006-03-30 | 2011-04-12 | Ptc Therapeutics Inc | métodos para produzir uma quantidade efetiva de uma proteìna de transleitura funcional codificada por uma sequência de ácido nucleico que compreende uma mutação não-sentido e para tratar, controlar e/ou prevenir uma doença |
| EP2081905B1 (fr) | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Composés sulfonyles modulant le récepteur cb2 |
| EP2698157B1 (fr) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
| EP2074084B1 (fr) | 2006-09-25 | 2013-08-28 | Boehringer Ingelheim International GmbH | Composés modulant le recepteur cb2 |
| WO2008098025A1 (fr) * | 2007-02-08 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Composés arylsulfonamide qui modulent le récepteur cb2 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| EP2527360B1 (fr) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5749162B2 (ja) | 2008-07-10 | 2015-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するスルホン化合物 |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| KR20110063485A (ko) | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물 |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
| BRPI1006128A2 (pt) | 2009-01-12 | 2016-11-01 | Cagen Inc | derivados de sulfonamida |
| US8410144B2 (en) | 2009-03-31 | 2013-04-02 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5546543B2 (ja) * | 2009-08-05 | 2014-07-09 | 第一三共株式会社 | スルホン誘導体 |
| MX2012001107A (es) * | 2009-08-05 | 2012-03-26 | Daiichi Sankyo Co Ltd | Derivado de amida. |
| US8383651B2 (en) | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2011041293A1 (fr) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose |
| US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| DK2531501T3 (en) | 2010-02-03 | 2014-02-24 | Takeda Pharmaceutical | APOPTOSESIGNALREGULERENDE KINASE 1 inhibitors |
| WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| US9145407B2 (en) | 2010-07-09 | 2015-09-29 | Pfizer Limited | Sulfonamide compounds |
| WO2012012307A1 (fr) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Composés sulfonylés qui modulent le récepteur cb2 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| CA2828405A1 (fr) * | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Molecules induisant l'apoptose et leurs utilisations |
| TWI529169B (zh) | 2011-07-29 | 2016-04-11 | 第一三共股份有限公司 | Ｎ－雜環取代醯胺衍生物 |
| WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
| WO2014151200A2 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
| EP2803668A1 (fr) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
| CA2942147C (fr) | 2014-03-06 | 2022-12-13 | Ptc Therapeutics, Inc. | Compositions pharmaceutiques et sels d'un acide benzoique 1,2,4-oxadiazole |
| WO2017075312A1 (fr) | 2015-10-30 | 2017-05-04 | Ptc Therapeutics, Inc. | Méthodes de traitement de l'épilepsie |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029159A1 (fr) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
-
1997
- 1997-06-03 JP JP10500782A patent/JP2000511903A/ja active Pending
- 1997-06-03 WO PCT/US1997/009536 patent/WO1997046556A1/fr not_active Application Discontinuation
- 1997-06-03 CA CA002257206A patent/CA2257206A1/fr not_active Abandoned
- 1997-06-03 AU AU33748/97A patent/AU712057B2/en not_active Ceased
- 1997-06-03 EP EP97929769A patent/EP0906310A4/fr not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029159A1 (fr) * | 1994-04-26 | 1995-11-02 | Merck & Co., Inc. | SULFAMIDES SUBSTITUES UTILISES COMME AGONISTES SELECTIFS VIS-A-VIS DES RECEPTEURS β3-ADRENERGIQUES, POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9746556A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3374897A (en) | 1998-01-05 |
| JP2000511903A (ja) | 2000-09-12 |
| AU712057B2 (en) | 1999-10-28 |
| EP0906310A1 (fr) | 1999-04-07 |
| CA2257206A1 (fr) | 1997-12-11 |
| WO1997046556A1 (fr) | 1997-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0906310A4 (fr) | BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES -g(b) 3? SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE | |
| GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| AU3723297A (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| IL131130A0 (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| HU9602951D0 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| EP2295453A3 (fr) | Peptide de suppression de l'appétit, ses compositions et son utilisation | |
| ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
| AU4714393A (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| HK1005648A1 (en) | Device for suturing blood vessels and the like | |
| AU2427297A (en) | Apparatus for facilitating the placement of sutures, ligatures and the like | |
| AU2598395A (en) | Surgical combination inject and snare apparatus | |
| HK1022835A1 (en) | Pharmaceutical composition for treatment of diabetes | |
| HK1031174A1 (en) | Compositions and methods for treating diabetes | |
| IL112205A0 (en) | Curcumin, analogues of curcumin and novel uses thereof | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| HUP9904075A3 (en) | Composition, for the treatment of asthma,containing loratadine and a decongestant | |
| HK1018271A1 (en) | Substituted benzylamines and their use for the treatment of depression | |
| EP0919576A4 (fr) | Nouveau copolymere, son procede de preparation et son utilisation | |
| IL113992A0 (en) | Use of copolymer-1 | |
| EP0858340A4 (fr) | Traitement combine du diabete et de l'obesite | |
| EP0852503A4 (fr) | Composition pour le traitement de la diarrhee, son utilisation et sa preparation | |
| AU4178497A (en) | HTm4, methods of treatment and assays, agonists and antagonists | |
| GB9606076D0 (en) | Diabetes treatment | |
| EP0969852A4 (fr) | Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite | |
| GB9614191D0 (en) | Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990107 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RIC1 | Information provided on ipc code assigned before grant |
Free format text: 6C 07D 413/12 A, 6C 07D 413/14 B, 6A 61K 31/47 B, 6A 61K 31/44 B |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19990720 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
| RTI1 | Title (correction) |
Free format text: OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE BETA-3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
|
| 17Q | First examination report despatched |
Effective date: 20000522 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20010804 |